Last reviewed · How we verify

DXM + Propofol

Seoul National University Hospital · FDA-approved active Small molecule

DXM (dextromethorphan) and propofol together provide dissociative anesthesia and analgesia through NMDA receptor antagonism and GABAergic potentiation.

DXM (dextromethorphan) and propofol together provide dissociative anesthesia and analgesia through NMDA receptor antagonism and GABAergic potentiation. Used for Anesthesia induction and maintenance (investigational combination).

At a glance

Generic nameDXM + Propofol
SponsorSeoul National University Hospital
Drug classDissociative anesthetic combination
TargetNMDA receptor (DXM); GABA-A receptor (propofol)
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Dextromethorphan is a non-competitive NMDA receptor antagonist that produces dissociative effects and analgesia. Propofol is a GABAergic agent that enhances inhibitory neurotransmission, producing sedation and hypnosis. The combination leverages complementary mechanisms for anesthetic and analgesic effects, potentially reducing required doses of each agent.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: